Company Data
89bio Inc.
Ticker
ETNB
Current Price
$10.96 -3.01%
Market Cap
$1.2B
Price Target
Refer to Report
Volume
960.0K
52wk Range
$5.9857 - $16.63
Overview
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).